Odonate
Odonate
ODTC
OTC
176038.40
USD
0.00%
About
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax..
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 0 |
| Three Month Average Volume | 0 |
| High Low | |
| Fifty-Two Week High | 49895 USD |
| Fifty-Two Week Low | 2849.5 USD |
| Fifty-Two Week High Date | 05 Feb 2024 |
| Fifty-Two Week Low Date | 09 May 2024 |
| Price and Volume | |
| Current Price | 17050 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.34% |
| Thirteen Week Relative Price Change | 459.06% |
| Twenty-Six Week Relative Price Change | -7.42% |
| Fifty-Two Week Relative Price Change | -9.29% |
| Year-to-Date Relative Price Change | -4.01% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 498.35% |
| Twenty-Six Week Price Change | 1.79% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | 13.67% |
| Year-to-Date Price Change | 13.67% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 17.6526 USD |
| Book Value Per Share (Most Recent Quarter) | 9.27128 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 17.6526 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 9.27128 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -11.97922 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -19.22401 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -13.58802 USD |
| Normalized (Last Fiscal Year) | -19.22401 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -19.22401 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -13.58802 USD |
| Including Extraordinary Items (Last Fiscal Year) | -19.22401 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -13.58802 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 20.39103 USD |
| Cash Per Share (Most Recent Quarter) | 12.34439 USD |
| Cash Flow Per Share (Last Fiscal Year) | -19.1563 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -13.49191 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -12.56315 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 284.79% |
| Tangible Book Value (5 Year) | 314.70% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 60.25% |
| EPS Change (Trailing Twelve Months) | 30.56% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -95,028,000 |
| Net Debt (Last Fiscal Year) | -157,265,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 966 |
| Price to Book (Most Recent Quarter) | 1.8K |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -113,562,000 |
| Free Cash Flow (Trailing Twelve Months) | -94,579,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -70.84% |
| Return on Assets (Trailing Twelve Months) | -66.98% |
| Return on Assets (5 Year) | -58.36% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -84.67% |
| Return on Equity (Trailing Twelve Months) | -86.14% |
| Return on Equity (5 Year) | -65.67% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -82.89% |
| Return on Investment (Trailing Twelve Months) | -83.00% |
| Return on Investment (5 Year) | -65.14% |